These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 1424072)

  • 1. New strategies in nonantibiotic treatment of gram-negative sepsis.
    Cohn J; Bone RC
    Cleve Clin J Med; 1992; 59(6):608-15. PubMed ID: 1424072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
    Talan DA
    Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunopathogenesis of abdominal sepsis.
    Weber GF; Swirski FK
    Langenbecks Arch Surg; 2014 Jan; 399(1):1-9. PubMed ID: 24121723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A.
    van Dissel JT; van Furth R; Compier BA; Feuth HD; Frolich M
    Lancet; 1993 Apr; 341(8850):959-60. PubMed ID: 8096292
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy of sepsis.
    Evans TJ; Cohen J
    J Med Microbiol; 1993 Apr; 38(4):237-9. PubMed ID: 8474114
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulminant septic shock caused by Capnocytophaga canimorsus in Italy: Case report.
    Piccinelli G; Caccuri F; De Peri E; Tironi A; Odolini S; Notarangelo LD; Gargiulo F; Castelli F; Latronico N; Facchetti F; Caruso A
    Int J Infect Dis; 2018 Jul; 72():3-5. PubMed ID: 29730383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock.
    Pollack M; Ohl CA
    Curr Top Microbiol Immunol; 1996; 216():275-97. PubMed ID: 8791745
    [No Abstract]   [Full Text] [Related]  

  • 10. Passive immunotherapy of gram-negative bacteremia, sepsis and septic shock.
    Spapen HD; Diltoer M; Huyghens LP
    Acta Clin Belg; 1993; 48(1):20-9. PubMed ID: 7684546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gram-negative bacterial sepsis in hospitals in the United States--natural history in the 1980s.
    Martin MA; Wenzel RP; Gorelick KJ
    Prog Clin Biol Res; 1991; 367():111-9. PubMed ID: 1924421
    [No Abstract]   [Full Text] [Related]  

  • 12. Sepsis and SIRS.
    Bone RC
    Nephrol Dial Transplant; 1994; 9 Suppl 4():99-103. PubMed ID: 7800276
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to tumour necrosis factor in the treatment of severe sepsis: rationale and early clinical experience.
    Cohen J
    Prog Clin Biol Res; 1991; 367():187-96. PubMed ID: 1924427
    [No Abstract]   [Full Text] [Related]  

  • 15. Macrophage migration inhibitory factor and innate immune responses to bacterial infections.
    Froidevaux C; Roger T; Martin C; Glauser MP; Calandra T
    Crit Care Med; 2001 Jul; 29(7 Suppl):S13-5. PubMed ID: 11445727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibodies in the treatment of septic shock].
    Trilla A; Alonso P
    Med Clin (Barc); 1992 Dec; 99(20):778-80. PubMed ID: 1460950
    [No Abstract]   [Full Text] [Related]  

  • 17. [Endotoxin adsortion as adjuvant therapy in gram negative severe sepsis].
    Candel FJ; Martínez-Sagasti F; Borges M; Maseda E; Herrera-Gutiérrez M; Garnacho-Montero J; Maynar FJ; Zaragoza R; Mensa J; Azanza JR
    Rev Esp Quimioter; 2010 Sep; 23(3):115-21. PubMed ID: 20844841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-based treatment of sepsis.
    Brandenburg K; Andrä J; Garidel P; Gutsmann T
    Appl Microbiol Biotechnol; 2011 May; 90(3):799-808. PubMed ID: 21369803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.